CAR-T Meeting 2023

Multivalent gamma-delta T-cells: promising agents for the treatment of cancers 0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks 8:25
CAR-T therapy in acute and chronic leukemias: current applications and future outlooks
John Gribben • 10 Feb 2023
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA 1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL 2:21
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL
Maksim Mamonkin • 10 Feb 2023
The importance of managing hematologic toxicity associated with CAR-T therapy 2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells 2:15
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner • 10 Feb 2023
Rapid CAR-T manufacturing and challenges in this space 1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells 1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
The content of VJRegenMed is intended for healthcare professionals